|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:affiliated_with
|
gptkb:DEF_Biotech
|
|
gptkbp:animal_model
|
xenograft model
|
|
gptkbp:bioavailability
|
moderate
|
|
gptkbp:casnumber
|
123456-78-9
|
|
gptkbp:chemical_formula
|
C12 H15 N3 O2
|
|
gptkbp:class
|
thiazole derivatives
|
|
gptkbp:clinical_trial
|
Phase I
NCT01234567
|
|
gptkbp:collaboration
|
gptkb:Partnerships
|
|
gptkbp:collaborations
|
gptkb:GHI_Research_Institute
|
|
gptkbp:composed_by
|
multi-step organic synthesis
|
|
gptkbp:discovered_by
|
gptkb:XYZ_Pharmaceuticals
|
|
gptkbp:dissolved
|
soluble in DMSO
|
|
gptkbp:drug_interactions
|
none reported
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:financial_stability
|
stable under room temperature
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
gptkbp:funding
|
government grant
|
|
gptkbp:future_plans
|
combination therapy studies
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
WPC-1129
|
|
gptkbp:impact
|
gptkb:significant
|
|
gptkbp:indication
|
gptkb:Oncology
|
|
gptkbp:invention
|
2025
patented
|
|
gptkbp:investigates
|
formulation stability
|
|
gptkbp:investment
|
high
|
|
gptkbp:is_effective_against
|
under investigation
|
|
gptkbp:knockouts
|
high
|
|
gptkbp:lifespan
|
4 hours
|
|
gptkbp:market_position
|
not yet marketed
|
|
gptkbp:mechanism_of_action
|
inhibitor of specific enzymes
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:phase_of_clinical_trials
|
Phase II
|
|
gptkbp:previous_name
|
N-(4-(2-(4-(trifluoromethyl)phenyl)thiazol-4-yl)thiazol-2-yl)phenyl)acetamide
|
|
gptkbp:project
|
preclinical
|
|
gptkbp:publication
|
gptkb:Journal_of_Medicinal_Chemistry
|
|
gptkbp:regulatory_compliance
|
under review
|
|
gptkbp:related_products
|
IND-123456
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_focus
|
tumor growth inhibition
|
|
gptkbp:research_institutes
|
gptkb:ABC_University
|
|
gptkbp:research_interest
|
growing
|
|
gptkbp:research_output
|
promising results
|
|
gptkbp:research_phase
|
discovery phase
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
under evaluation
|
|
gptkbp:safety_measures
|
ongoing
completed
active monitoring
|
|
gptkbp:side_effect
|
headache
nausea
|
|
gptkbp:structure
|
contains thiazole rings
|
|
gptkbp:targets
|
gptkb:EGFR
specific cancer cells
|
|
gptkbp:therapeutic_index
|
favorable
|
|
gptkbp:used_in
|
pharmaceutical research
|
|
gptkbp:weight
|
233.27 g/mol
|
|
gptkbp:bfsParent
|
gptkb:USCGC_Richard_Snyder
|
|
gptkbp:bfsLayer
|
7
|